Interleukin-18-receptor proteins
AssigneeKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
InventorsKAKUJI TORIGOE, SHIMPEI USHIO, TOSHIO KUNIKATA, MASASHI KURIMOTO
Life of this patent
Estimating the term…
Loading patent…
AssigneeKabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
InventorsKAKUJI TORIGOE, SHIMPEI USHIO, TOSHIO KUNIKATA, MASASHI KURIMOTO
Estimating the term…
Disclosed are a receptor protein which recognize a novel cytokine, i.e., interleukin-18, a monoclonal antibody specific to the protein, and uses thereof. The receptor protein is useful as pharmaceutical to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction. The monoclonal antibody specifically reacts with interleukin-18, exhibiting efficacy in purification, detection and inhibition of interleukin-18.
Interleukin-18 receptor protein.
Dependencies are inferred from the claim text.
From the US filing history. Foreign family members aren’t listed.
Backward citations are indexed for grants only.
Against receptors, cell surface antigens or cell surface determinants: against receptors for cytokines, lymphokines, interferons
For cytokines; for lymphokines; for interferons: for interleukins [IL]
Medicinal preparations containing peptides
Peptides
Term end not estimated
USPTO file history isn’t available for this patent, so only indexed dates are shown.
Drawings are temporarily unavailable. Open the PDF at USPTO
1. Field of the Invention
This invention relates to a novel receptor protein recognizing a specific cytokine, more particularly, to a novel protein composing interleukin-18 receptor (hereinafter abbreviated as “IL-18R”) or IL-18R protein, as well as to a monoclonal antibody specific to the IL-18R protein.
2. Description of the Prior Art
FIG. 1 shows that the monoclonal antibody MAb #117-10C binds to L428 cells and IL-18R while competing with IL-18.
FIG. 2 is an image of intermediate tone given on display, which shows IL-18R on gel electrophoresis visualized by the Western blotting method using the monoclonal antibody MAb #117-10C.
FIG. 3 shows the inhibitory action of the monoclonal antibody MAb #117-10C on the activity of IL-18.
The symbol “117-VL-VH cDNA” means the cDNA which encodes the variable regions of both the heavy and light chains in the monoclonal antibody MAb #117-10C.
The symbol “Pcmv” means the cytomegalo virus promotor.
The IL-18R protein of this invention can be characterized by a property of recognizing IL-18. As to IL-18, those of human and mouse origins commonly consisting of 157 amino acids have been documented: Human IL-18 bears the amino acid sequence of SEQ ID NO:26 (where the amino acid with symbol “Xaa” represents either isoleucine or threonine), while mouse counterpart, the amino acid sequence of SEQ ID NO:27 (where the amino acid with symbol “Xaa” represents either methionine or threonine). The IL-18R protein has sites for recognizing and binding to IL-18. Binding of IL-18 to the sites expressed on immunocompetent cells can induce the production of IFN-γ in the cells. The IL-18R protein usually loses the property after being heated at 100° C. for 5 minutes. The IL-18R protein in an IL-18-bound form usually appears to have a molecular weight of about 50,000-200,000 daltons on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (hereinafter abbreviated as “SDS-PAGE”) in the presence of a reducing agent. The IL-18R protein may bear as partial amino acid sequence one or more amino acid sequences of SEQ ID NOs:3 to 10.